New Delhi   

New feather in CSIR's cap

Special Correspondent

NEW DELHI: The Council of Scientific and Industrial Research (CSIR) has added another feather to its cap with a U.S.-based pharmaceutical company choosing to furtherdevelop and commercialise a new molecule developed by the Council's Chandigarh-based Institute of Microbial Technology for busting blood clots.

The company, Nostrum Pharmaceuticals, presented a cheque for $100,000 to the Institute earlier this week as the first payment for acquiring worldwide licensing rights for the molecule, which promises to be better than Streptokinase, the traditional remedy for blood clots.

Speaking to reporters, Yatindra Prashar, President of Symmetrix Pharmaceuticals, an affiliate of Nostrum Pharmaceuticals, said the firm was attracted to the new molecule as it was designed to be active only in the vicinity of blood clots and, therefore, would overcome the risk of severe bleeding.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

A jolly good show from Bollywood
Raids trigger panic among Councillors
DU to make its campus `equal'
Unique talent hunt for street kids
Sri Lankan Minister thanks India
Janhastakshep seeks probe into land deals
"Contract killer" held
Live operative workshop on robotic urological surgery
Adding colour to the rain
Ex-DU employee held on cheating charge
Minister visits industrial area
Consumer helpline gets good response
New feather in CSIR's cap
A new front in the offing
DUTA calls for bandh on August 7
Woman power
Two cops detained for non-appearance
Around the City
Briefly
In the Capital Today

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu